IGM Biosciences, Inc. (IGMS) reported quarterly earnings of $1.58 per share for the period ending June 2025, significantly surpassing the Zacks Consensus Estimate of a loss of $0.3 per share. This marks a drastic improvement from a loss of $0.79 per share in the same quarter last year. Additionally, the company’s revenues reached $143.62 million, exceeding estimates by 4,388.22%, compared to revenues of $1.25 million a year ago.
IGM has now surpassed consensus EPS estimates twice over the last four quarters. Despite this, its stock has experienced a decline of approximately 79.4% year-to-date, while the S&P 500 has risen by 8.2%. Currently, the consensus EPS estimate for the upcoming quarter stands at -$0.31, with expected revenues of $3.21 million.
